Interviews

In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the background and findings from a study comparing patients who underwent thymectomy and nephrectomy.

Jose Lutzky, MD, discusses the innovative tumor-inflitrating lymphocyte therapy for the treatment of relapsed or refractory melanoma.

In an interview with Targeted Oncology, Joe Leach, MD, highlighted the current state and future prospects of treating patients with small cell lung cancer.

Kim N. Chi, MD, FRCPC, discusses how the findings from the phase 3 MAGNITUDE trial translate into everyday practice.

Gabriel N. Hortabagyi, MD, FACP, provides an overview of the phase 3 NATALEE trial evaluating the combination of ribociclib with endocrine therapy as adjuvant treatment in patients with hormone receptor-positive/HER2-negative early breast cancer.

Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.

Binod Dhakal, MD, MS, discusses the basis of the FDA approval of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma that has been treated with at least 1 prior line of therapy and is refractory to lenalidomide.

Halle Moore, MD, discusses some of the main concerns that patients with breast cancer have about fertility after treatment.

For Melanoma and Skin Cancer Awareness Month, Nayoung Lee, MD, discussed evolving paradigms in skin cancer diagnosis and prevention.

Ira Zackon, MD, discusses the results of a real-world study evaluating racial and socioeconomic disparities among patients with chronic lymphocytic leukemia.

Ariel Lopez-Chavez, MD, emphasizes the critical need for improved second-line therapies in small cell lung cancer.

In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.

Ariel Lopez-Chavez, MD, discusses ongoing research in the small cell lung cancer space.

In an interview with Targeted Oncology, Shilpa Gupta, MD, discussed the rationale and potential significance of the MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma.

For World Ovarian Cancer Day, Eirwen M. Miller, MD, discussed the current state of ovarian cancer treatment, new developments in the space, and unmet needs.

Sanjay K. Juneja, MD, delves into what being recognized as an oncology icon for Targeted Oncology means to him.

In an interview with Targeted Oncology, Kayla Giannetti, MSN, APRN-CNP, discussed the background of the study, along with its findings and implications for community oncologists.

Raajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.

In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.

Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.

Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.

Brian Slomovitz, MD, details findings from the innovaTV 301 trial investigating tisotumab vedotin for the treatment of recurrent or metastatic cervical cancer.

C. Ola Landgren, MD, PhD, discussed the FDA’s unanimous ODAC vote supporting minimal residual disease as an accelerated approval end point in multiple myeloma and the implications of this vote in the myeloma research field.

Regina Barragan-Carrillo, MD, discusses results of a study which sought to assess the association between thymectomy and incidence of renal cell carcinoma.

Lori J. Wirth, MD, discusses some of the ongoing clinical trials investigating innovative therapies or combinations for the treatment of patients with thyroid cancer.

Lucia Masarova, MD, PhD, elaborated on the latest updates across myeloproliferative neoplasms, focusing on significant studies and emerging therapeutic approaches.

Ariel Lopez-Chavez, MD, discusses the potential of tarlatamab and its use in the frontline setting for the treatment of patients with small cell lung cancer.

Binod Dhakal, MD, MS, discusses the potential risk of secondary cancers like lymphoma and leukemia sometimes seen with chimeric antigen receptor T-cell therapies.

In an interview with Targeted Oncology for Head and Neck Cancer Awareness Month, Noel Laudi, MD, MRCP, discussed the link between human papillomavirus infection and head and neck cancers.

John M. Burke, MD, discusses results from a phase 2 study which evaluated brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for the treatment of early-stage and advanced classical Hodgkin lymphoma.